Aachen papers per year
Papers 539
-
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Jacob P. Laubach, Jonathan L. Kaufman, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +22 more
24citations -
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, +21 more
24citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Hervé Avet‐Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz C. Offner, Vincent H. J. van der Velden, Denis Caillot, +25 more
21citations -
Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela Maria Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, +21 more
21citations -
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial
Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, +26 more
19citations -
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, +37 more
18citations
Most active Aachen authors
-
Tim H. Brümmendorf 16,145 citations overall53 papers
-
Steffen Koschmieder 11,677 citations overall46 papers
-
Jens Panse 10,288 citations overall40 papers
-
Joost S.P. Vermaat 3,482 citations overall40 papers
-
Linda Köster 1,844 citations overall39 papers
-
Edgar Jost 3,752 citations overall31 papers
-
Dirk‐Jan Eikema 1,017 citations overall29 papers
-
Hendrik Veelken 10,266 citations overall25 papers
-
Fabian Beier 3,900 citations overall23 papers
-
Martina Margrit Crysandt 2,348 citations overall23 papers
-
Luuk A. Gras 5,079 citations overall21 papers
-
JESSICA T. VERMEULEN 10,466 citations overall20 papers
-
Liesbeth C. de Wreede 4,718 citations overall18 papers
-
Régis Peffault de Latour 20,463 citations overall14 papers
-
Antonio Maria Risitano 16,882 citations overall14 papers